GUTS — Fractyl Health, Inc. Common Stock

Summary of Fractyl Health Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Net Income: Reported net income of $9.2 million for Q1 2026, a significant improvement from a net loss of $23.7 million in Q1 2025, primarily due to a $30.1 million noncash accounting change in warrant liabilities.
• Research and Development Expenses: Decreased to $15.6 million from $19.4 million year-over-year, attributed to reduced spending on Revita and Rejuva programs.
• SG&A Expenses: Remained stable at $5.2 million compared to $5.3 million in the previous year.
• Adjusted EBITDA: Negative $18 million, an improvement from negative $23 million in Q1 2025.
• Cash Position: As of March 31, 2026, Fractyl had approximately $63.2 million in cash, expected to fund operations into early 2027.

2. Strategic Updates and Business Highlights

• Revita Program: Strong clinical signal confirmed with positive data from the REMAIN-1 Midpoint cohort study. The pivotal trial is fully randomized with over 300 participants and is on track for top-line data in early Q4 2026.
• Commercial Pathway: Favorable market dynamics due to the approval of oral GLP-1 therapies and expanded access for Medicare and Medicaid beneficiaries. The company is also pursuing a new reimbursement pathway (RAPID) that could accelerate commercialization.
• Rejuva Program: Received EU regulatory authorization to initiate a Phase 1/2 study for RJVA-001, a gene therapy targeting Type 2 diabetes.

3. Forward Guidance and Outlook

• Clinical Milestones: Three major data readouts expected in the next six months, including 12-month data from REVEAL-1 and REMAIN-1 Midpoint cohorts, and pivotal data in early Q4 2026.
• Regulatory Submission: Anticipated de novo submission to the FDA in late Q4 2026, contingent on successful pivotal data.
• Cash Runway: Management reaffirmed that the current cash position will support operations through critical upcoming milestones without the need for additional capital raises.

4. Bad News, Challenges, or Points of Concern

• Market Competition: The approval of oral GLP-1 therapies may increase competition, although initial data suggests patients are not refilling these medications as expected, indicating a continued need for alternatives like Revita.
• Regulatory Risks: While management is confident in the pivotal trial's success, any adverse outcomes could impact the timeline for FDA submission and market entry.
• Operational Risks: The ongoing execution of clinical trials and the need for high patient retention rates remain critical for success.

5. Notable Q&A Insights

• De Novo Submission: Management indicated that the de novo pathway allows for flexibility in regulatory submissions, where totality of evidence rather than a single metric will be considered.
• Rejuva Enrollment Timeline: Initial dosing will focus on safety and feasibility, with preliminary data expected within 8 weeks after the first patient is dosed.
• Feedback from DDW: Positive engagement from leading gastroenterologists at the Digestive Disease Week, indicating strong interest and support for Revita among clinical champions.
• IP Portfolio: Continued strengthening of the intellectual property portfolio for both Revita and Rejuva, although specific new patents were not disclosed during the call.

This summary encapsulates the key points from Fractyl Health's Q1 2026 earnings call, highlighting both the positive developments and potential challenges the company faces moving forward.